METHOD FOR CHOOSING MANAGEMENT APPROACH TO PREGNANT WOMEN WITH MODERATE PREECLAMPSIA Russian patent published in 2013 - IPC G01N33/49 

FIELD: medicine.

SUBSTANCE: pregnant woman's blood is examined for the concentration of angiogenic factors sFlt-1 - soluble fms-like tyrosine kinase and PIGF placental growth factor. The coefficient K which is the sFlt-1 to PIGF relation is calculated. If K is less than 832 pg/ml, pregnancy prolongation with underlying therapy aiming at pregnancy prolongation, as well as with underlying integrated therapy of preeclampsia under the control of clinical-laboratory values, general health of the pregnant woman, functional state of the foetus and level of angiogenic factors is required. The delivery in the given group of the pregnant woman is considered to be indicated if K reaches the values equal to 832 pg/ml or more, or if observing signs of foetus deterioration, or if observing more severe clinical course of preeclampsia. If 832≤K≤598 pg/ml, the delivery required may be delayed by a period of time for prevention of foetus's respiratory distress syndrome.

EFFECT: method enables choosing a correct management approach to the pregnant women implying no threats for mother and foetus's lives.

4 ex, 3 cl